JP2005528921A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528921A5
JP2005528921A5 JP2004511543A JP2004511543A JP2005528921A5 JP 2005528921 A5 JP2005528921 A5 JP 2005528921A5 JP 2004511543 A JP2004511543 A JP 2004511543A JP 2004511543 A JP2004511543 A JP 2004511543A JP 2005528921 A5 JP2005528921 A5 JP 2005528921A5
Authority
JP
Japan
Prior art keywords
seq
patient
drug
level
fractalkine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004511543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528921A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/018570 external-priority patent/WO2003104484A1/en
Publication of JP2005528921A publication Critical patent/JP2005528921A/ja
Publication of JP2005528921A5 publication Critical patent/JP2005528921A5/ja
Withdrawn legal-status Critical Current

Links

JP2004511543A 2002-06-10 2003-06-10 Ｃｘ３ｃｒ１修飾物質を用いる糖尿病の治療および診断の方法 Withdrawn JP2005528921A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38769902P 2002-06-10 2002-06-10
PCT/US2003/018570 WO2003104484A1 (en) 2002-06-10 2003-06-10 Methods of treating and diagnosing diabetes with cx3cr1 modulators

Publications (2)

Publication Number Publication Date
JP2005528921A JP2005528921A (ja) 2005-09-29
JP2005528921A5 true JP2005528921A5 (enExample) 2006-08-10

Family

ID=29736354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004511543A Withdrawn JP2005528921A (ja) 2002-06-10 2003-06-10 Ｃｘ３ｃｒ１修飾物質を用いる糖尿病の治療および診断の方法

Country Status (6)

Country Link
US (1) US20060160076A1 (enExample)
EP (1) EP1511850A4 (enExample)
JP (1) JP2005528921A (enExample)
AU (1) AU2003243532A1 (enExample)
CA (1) CA2487438A1 (enExample)
WO (1) WO2003104484A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103684A2 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
EP2023144A1 (en) * 2007-08-01 2009-02-11 Sanofi-Aventis Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
EP4050027A3 (en) 2012-02-27 2022-11-30 Ablynx N.V. Cx3cr1-binding polypeptides
WO2013130492A1 (en) 2012-03-01 2013-09-06 The Regents Of The University Of California Novel target for diagnosis and treatment of diabetes and cardiovascular diseases
WO2015026884A1 (en) * 2013-08-21 2015-02-26 Boehringer Ingelheim International Gmbh Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
CN103656639B (zh) * 2013-12-18 2015-02-18 南方医科大学南方医院 不规则趋化因子的中和抗体用于制备消除糖尿病心肾功能损害不良代谢记忆的药物的用途
CN109891237B (zh) 2016-10-24 2022-08-23 诺和诺德股份有限公司 胰岛素制剂的生物测定法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2128208C (en) * 1992-11-17 2004-01-06 Ronald Godiska Novel seven transmembrane receptors
US6107475A (en) * 1992-11-17 2000-08-22 Icos Corporation Seven transmembrane receptors
US6699677B1 (en) * 1999-12-20 2004-03-02 Chemocentryx, Inc. Tethered ligands and methods of use

Similar Documents

Publication Publication Date Title
Mannucci et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects
Hu et al. Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population
Andreelli et al. Defective regulation of phosphatidylinositol-3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin-dependent diabetes mellitus patients
Duric et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects
Straub et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression
Vlassara Serum advanced glycosylation end products: a new class of uremic toxins?
JP2006502702A5 (enExample)
JP2005528921A5 (enExample)
CN105385774B (zh) Tmf1作为帕金森症诊断标志物的用途
Wu et al. SLC22A1 rs622342 Polymorphism Predicts Insulin Resistance Improvement in Patients with Type 2 Diabetes Mellitus Treated with Metformin: A Cross‐Sectional Study
Chidambaram et al. Replication of genome-wide association signals in Asian Indians with early-onset type 2 diabetes
CN112795645B (zh) 一种用于指导人高血糖用药的试剂盒
Ha et al. Elevation of urinary βig-h3, transforming growth factor-β-induced protein in patients with type 2 diabetes and nephropathy
CN111925419B (zh) 一种多肽作为嗅觉受体Olfr109拮抗剂配体的应用
JP2009516155A5 (enExample)
Al-Azzam et al. The associations of polymorphisms of TSH receptor and thyroid hormone receptor genes with L-thyroxine treatment in hypothyroid patients
JP2005529603A5 (enExample)
WO2019051073A1 (en) MODIFIED FIBROBLAST GROWTH FACTOR 21 (FGF-21) FOR USE IN NON-ALCOHOLIC STÉATOHÉPATITE (NASH) TREATMENT METHODS
JP2007500005A5 (enExample)
JP2006500002A5 (enExample)
RU2005127807A (ru) Применение нового полиморфизма в гене hsgki для диагностики гипертонии и применение генов семейства sgk для диагностики и терапии синдрома удлиненного q/t-периода
Hayashino et al. Normal fasting plasma glucose levels and type 2 diabetes: the high-risk and population strategy for occupational health promotion (HIPOP-CHP) study
CN1157406C (zh) 新的atp敏感性钾离子通道蛋白和其基因
KR102659625B1 (ko) Thada 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
US20130302833A1 (en) Method for control of invasion and use of adiponectin